Ensysce Biosciences, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
16.2M
on 2026-06-30, from 489K on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-15 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
S-3 of 2024-10-09. Not read yet. S-3 ↗
6 of its filings are not read yet.
Warrants
254K
Warrants of every class as tagged in the XBRL facts on 2026-04-23, exercise price $0.484. 10-Q ↗
Cash
0.3 quarters
$677K on 2026-06-30 ÷ $2.2M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-08-05 | Private placement | 120,260 | $321.79 | $43.0M | 8-K ↗ |
| 2025-11-13 | Registered direct offering | 665,922 | not read | not read | 424B5 ↗ |
| 2025-11-13 | Registered direct offering | 2,487 | not read | $1.7M | 8-K ↗ |
| 2025-03-30 | Public offering incl. 0.08M pre-funded | 315,188 | $3.49 | $1.1M | 424B5 ↗ |